Post hoc analysis of 3 PsA/SPA trials: no effect of tobacco 🚬 on TOFA efficacy But numerically higher TEAEs Contrasting w/ data from real world TNF Interesting data but small sample size & events N https://t.co/gv8uvcThMD Abs#1036 #ACR22 @Rheumnow https://t.co/HCJT0XF1tg

• Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Anky…

DANBIO registry: 1600+ pts RA, AxSpA, PsA Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111) Maintenance at 1yr: >80% > withdrawal in original IFX naive, but higher BL DA Do second time switchers do better because of past switch experience? Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz

Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA. Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity. @RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M

Abstr #1494 determinants of clinically important worsening (CIW) of early axSpA - CIW = ASDAS ↑ > 0.9 b/w 2 visits - Tender Joint count and ASAS-NSAID score associated w/ CIW - MRI SI Jt inflammation & structural damage predictive of CIW @RheumNow #ACR22 https://t.co/Dgeh25BaWM

BASDAI and ASDAS performed similarly in axPsA pts, both demonstrating weak correlations w/ peripheral arthritis and moderate/strong correlations w/ pt fatigue and pain. Abs 1037 #ACR22 @RheumNow https://t.co/WRQx1hkIll https://t.co/kJVIWyVv2w

• Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients wit…

Osteoporotic fx in AS Abstract #0388 #ACR22 @RheumNow 🦴2k adults in RISE, mean age 68y, 44% female, 76% white 🦴Higher risk with: older age, increased comorbidity index, OP history, chronic use of opioids, low BMI 🦴Men and women were equally likely to fracture

Early TNFi use and cardiovascular events in AS Abstract #0415 #ACR22 @RheumNow 📍17.6k patients, 91% male, 80% white 📍TNFi initiators were younger with lower prev. of HTN and DM 📍TNFi was associated with higher risk of incident CVD, CVA, and MACE https://t.co/7bCkfk7EYY

axPsA and AS adult pts exhibit different genetic risk factors & serum IL-17 levels. GUS demonstrated significant pharmacodynamic effects and clinical improvement in axPsA and non-axPsA pts. Abs 1038 #ACR22 @RheumNow https://t.co/9Rjw7usO8J

• Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Ankylo…

What neonatal factors could affect development into axSpA? Turns out antibiotic exposure (6.2x more likely). Mode of delivery, early diet (milk vs. formula), maternal smoking (!!) did not show association. @RheumNow #ACR22 Abs#0868 #ACRBest https://t.co/roCAj5YsCt

Other potential mechanisms for survival selection against the plague via MHC presentation to CD8 T cells. May be associated with SpA/HLA B27 @RheumNow @HRheuminations #ACR22 #rheuminations https://t.co/Rv117B4IYp

Deodhar et al. Bimekizumab (IL-17A/Fi) in nr-axSpA. Efficacy shown across all outcomes. Confirms bimekizumab works across spectrum of axSpA (not surprisingly). @RheumNow #ACR22 Abstr#0544 https://t.co/XVGBgBQpTH https://t.co/39zW5Ex9xh

• Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients wi…

Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal progression in AS. But... for high risk patients there may be some benefit - see figure. @RheumNow #ACR22 Abstr#0546 https://t.co/xo9Uy6aX71 https://t.co/vZgaoeEQn4

• COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy ver…

Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work. 12 months. Only 34% of withdrawal group in remission vs 84% full dose and 68% reduced dose group. @RheumNow #ACR22 Abstr#0545 https://t.co/Fa5YgT9FYk https://t.co/9C8ShI9qjk

• Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatm…